Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

12.20 -0.35 (-2.79%)
Streaming Delayed Price Updated: 3:21 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
34 35 Next >
News headline image
MindMed Provides Overview of Clinical Progress and Corporate Updates at Investor Day
From Mind Medicine
Via Business Wire
News headline image
Upward Trend In Major Psychedelic Compound-Based Research & Development Stocks Continue ↗
There are 6 constituents in our munKNEE Psychedelic Drug Stocks Index and 5 of them advanced this week and are now all up MTD. 
Via Talk Markets
News headline image
FCM Denounces MindMed’s Manipulation of Corporate Machinery to Protect Incumbent Board of Directors
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
News headline image
MindMed Adjourns Annual General Meeting of Shareholders
From Mind Medicine
Via Business Wire
News headline image
Major Psychedelic Compound-Based Research & Development Stocks: June Update ↗
Psychedelic Drug Stocks Index has been revamped with the removal of Cybin (CYBN) which has dropped below $100M in market capitalization leaving 6 constituents in the Index 
Via Talk Markets
News headline image
Creso Pharma's LOI For Import Of Swiss MDMA And Psilocybin Therapeutics To Australia ↗
Australia-based cannabis and psychedelics company Creso Pharma Ltd. (OTCMKTS: COPHF) inked a Letter of Intent (LOI) with Swiss pharmacy Apotheke Dr. 
Via Benzinga
News headline image
MindMed Urges Shareholders to Vote TODAY for Company Nominees Ahead of June 13th Deadline
From MindMed
Via Business Wire
News headline image
Leading Proxy Advisory Firm Glass Lewis Recommends MindMed Shareholders Vote FOR All Six Company Nominees
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
FCM Plans for MM-120 (LSD) FDA Approval in 2026 And Extends Share Lockup Until June 15, 2026
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
News headline image
MindMed to Host Investor Day June 2023
From Mind Medicine
Via Business Wire
News headline image
Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study ↗
Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud 
Via Benzinga
News headline image
Leading Proxy Advisory Firm ISS Recommends MindMed Shareholders Vote FOR All Six Company Nominees
From MindMed
Via Business Wire
News headline image
FCM Predicts Psychedelic Revolution In 2024: Urges Shareholders to Position MindMed for Success with a Reconstituted Board
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
News headline image
May Summary Of Largest Psychedelic Compound-Based Drug Stock Performances ↗
Only two of the seven largest psychedelic compound-based drug stocks tracked, advanced in May. 
Via Talk Markets
News headline image
MindMed to Participate at Upcoming Investor Conferences
From Mind Medicine
Via Business Wire
News headline image
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More ↗
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga
News headline image
FCM Pledges to Lock Up its MindMed Shares Until June 2025 to Demonstrate its Alignment with Fellow Shareholders and Confidence in its Plan to Restore MindMed
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
News headline image
MindMed And FCM Holdings' Dispute Over Clinical Path Forward Deepens ↗
The proxy battle over MindMed’s (NASDAQ: MNMD) control has now evolved to each side requesting their position on what is best for the company's future to be validated by independent sources, vis-a-vis... 
Via Benzinga
News headline image
FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
News headline image
MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed Calls FDA Experts To Validate LSD Drug Development Strategy ↗
In a new chapter of the management quarrel between MindMed (NASDAQ: MNMD) executives and shareholder group FCM Holdings, t 
Via Benzinga
News headline image
MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
From Mind Medicine (MindMed) Inc.
Via Business Wire
News headline image
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
From MindMed
Via Business Wire
News headline image
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More ↗
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
Via Benzinga
News headline image
MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected ↗
MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed. 
Via Benzinga
News headline image
MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
From MindMed
Via Business Wire
News headline image
FCM Holdings Accuse MindMed Braintrust Of 'Pursuing Misguided Clinical Path for MM-120' ↗
Mind Medicine (NASDAQ: MNMD) activist shareholders FCM MM Holdings are at it again. 
Via Benzinga
News headline image
FCM Director Nominees Will Put MindMed Drug Development Process Back on Track
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
News headline image
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More ↗
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
News headline image
MindMed Reports Q1 2023 Financial Results, Business Highlights, Upcoming Elections ↗
Clinical-stage biopharma company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has reported its unaudited financial results for the quarter ended March 31, 2023, and shared the period’s business... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.